Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept and Cytokine Levels in Diabetic Macular Edema
NCT02441907Phase 4Completed
- Sponsor
- Unity Health Toronto
- Start
- Aug 2015
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by Unity Health Toronto. Started Aug 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02441907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441907.